AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 82 filers reported holding AVADEL PHARMACEUTICALS PLC in Q3 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,935,634 | -31.9% | 285,013 | +8.9% | 0.00% | 0.0% |
| Q2 2023 | $4,312,470 | +113.4% | 261,679 | +18.6% | 0.00% | 0.0% |
| Q1 2023 | $2,020,650 | +123.8% | 220,595 | +74.8% | 0.00% | – |
| Q4 2022 | $903,000 | +92.9% | 126,174 | +35.0% | 0.00% | – |
| Q3 2022 | $468,000 | +71.4% | 93,480 | -16.4% | 0.00% | – |
| Q2 2022 | $273,000 | -69.0% | 111,881 | -13.2% | 0.00% | – |
| Q1 2022 | $880,000 | -23.5% | 128,849 | -9.4% | 0.00% | – |
| Q4 2021 | $1,150,000 | -71.1% | 142,251 | -64.9% | 0.00% | -100.0% |
| Q3 2021 | $3,975,000 | +47.4% | 405,651 | +1.7% | 0.00% | 0.0% |
| Q2 2021 | $2,697,000 | -24.5% | 398,755 | +0.3% | 0.00% | 0.0% |
| Q1 2021 | $3,573,000 | +43.1% | 397,713 | +6.4% | 0.00% | 0.0% |
| Q4 2020 | $2,497,000 | +32.0% | 373,785 | -0.4% | 0.00% | 0.0% |
| Q3 2020 | $1,892,000 | -31.8% | 375,425 | +9.3% | 0.00% | 0.0% |
| Q2 2020 | $2,776,000 | -19.8% | 343,525 | -21.2% | 0.00% | -50.0% |
| Q1 2020 | $3,462,000 | -4.5% | 436,020 | -9.2% | 0.00% | 0.0% |
| Q4 2019 | $3,627,000 | +14.1% | 480,460 | -37.2% | 0.00% | +100.0% |
| Q3 2019 | $3,180,000 | +48.9% | 764,570 | +3.5% | 0.00% | 0.0% |
| Q2 2019 | $2,135,000 | +176.2% | 738,970 | +37.6% | 0.00% | – |
| Q1 2019 | $773,000 | -40.5% | 537,101 | +6.6% | 0.00% | -100.0% |
| Q4 2018 | $1,300,000 | -7.6% | 503,870 | +56.2% | 0.00% | – |
| Q3 2018 | $1,407,000 | -26.9% | 322,585 | +2.0% | 0.00% | -100.0% |
| Q2 2018 | $1,925,000 | +10.4% | 316,314 | +32.1% | 0.00% | 0.0% |
| Q1 2018 | $1,744,000 | +0.9% | 239,531 | +12.7% | 0.00% | 0.0% |
| Q4 2017 | $1,728,000 | -19.4% | 212,518 | +4.1% | 0.00% | 0.0% |
| Q3 2017 | $2,143,000 | +4.1% | 204,168 | +9.4% | 0.00% | 0.0% |
| Q2 2017 | $2,058,000 | +12.5% | 186,617 | -1.2% | 0.00% | 0.0% |
| Q1 2017 | $1,830,000 | – | 188,977 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,498,838 | $22,889,355 | 11.72% |
| Knoll Capital Management, LLC | 500,000 | $4,580,000 | 7.06% |
| GENDELL JEFFREY L | 5,301,914 | $48,565,532 | 4.55% |
| COWEN AND COMPANY, LLC | 3,732,778 | $34,192,246 | 4.02% |
| Tri Locum Partners LP | 1,327,097 | $12,156,209 | 3.70% |
| Samsara BioCapital, LLC | 1,409,409 | $12,910,186 | 2.67% |
| Altium Capital Management LP | 500,000 | $4,580,000 | 2.54% |
| Vivo Capital, LLC | 3,761,438 | $34,454,772 | 2.39% |
| RTW INVESTMENTS, LP | 5,741,939 | $52,596,161 | 1.10% |
| Knott David M Jr | 291,113 | $2,667 | 1.05% |